1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Industry Market Research Reports

Chronic Disease Industry Market Research Reports

1-30 of about 2500 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Australian Foundation Investment Investor presentation

  • January 2022
  • 27 pages
  • Australia
  • Oceania
  • Wholesaling
  • Webcast
  • Investor presentation
  • Company
View report >

Avanos Medical Investor presentation

  • January 2022
  • 4 pages
  • United States
  • North America
  • Arthritis
  • Investor presentation
  • Company
View report >

Krystal Biotech Investor presentation

  • January 2022
  • 3 pages
  • World
  • United States
  • Clinical Development
  • Genetic Disorder
  • Investor presentation
  • Company
View report >

lifemd Investor presentation

  • January 2022
  • 3 pages
  • United States
  • Telemedicine
  • E-Healthcare
  • Investor presentation
  • Company
View report >

Therapeutics Inc Analyst report

  • January 2022
  • 4 pages
  • United States
  • North America
  • Chronic Pain
  • Depression
  • Broker research
  • Company
View report >

Olympus Investor presentation

  • January 2022
  • 41 pages
  • World
  • Endoscope
  • Urology
  • Investor presentation
  • Company
  • Cancer Incidence
  • Colorectal Cancer Screening Coverage
View report >

ZILRETTA Investor presentation

  • January 2022
  • 20 pages
  • World
  • Chronic Pain
  • Hospital
  • Investor presentation
  • Company
View report >

Nevro Investor presentation

  • January 2022
  • 26 pages
  • World
  • Chronic Pain
  • Pain Relief
  • Investor presentation
  • Company
  • Hospital Admission
View report >

Horizon Therapeutics Company report

  • January 2022
  • 31 pages
  • World
  • United States
  • Musculoskeletal Disorder
  • Pathology
  • Company research
  • Company
  • Drug Approval
View report >

RCC Investor presentation

  • January 2022
  • 34 pages
  • United States
  • Cardiovascular Disease
  • Investor presentation
  • Company
  • Surgical Procedures Performed
View report >

Aurinia Pharmaceuticals Investor presentation

  • January 2022
  • 6 pages
  • United States
  • Musculoskeletal Disorder
  • Clinical Trial
  • Investor presentation
  • Company
View report >

Cytokinetics Investor presentation

  • January 2022
  • 3 pages
  • United States
  • Clinical Trial
  • Cardiovascular Disease
  • Investor presentation
  • Company
View report >

Omega Diagnostics Group Analyst report

  • January 2022
  • 7 pages
  • Canada
  • North America
  • Pathology
  • Infectious Disease
  • Broker research
  • Company
View report >

AlzeCure Pharma AB Analyst report

  • January 2022
  • 7 pages
  • Australia
  • Oceania
  • Chronic Pain
  • Dementia
  • Broker research
  • Company
  • Drug Approval
View report >

Angion Investor presentation

  • January 2022
  • 31 pages
  • United States
  • World
  • Renal Disease
  • Clinical Trial
  • Investor presentation
  • Company
  • Dropout Rate
View report >

ABIOMED Analyst report

  • January 2022
  • 9 pages
  • United States
  • World
  • Specialty Hospital
  • Health Services
  • Broker research
  • Company
  • Drug Approval
View report >

Quantum Genomics Corp. Analyst report

  • January 2022
  • 10 pages
  • World
  • Asia
  • Pharmaceutical
  • Hypertension
  • Broker research
  • Company
  • Number Of Enterprises
  • Dates Price
View report >

Galapagos Quarterly report

  • January 2022
  • 7 pages
  • Europe
  • World
  • Arthritis
  • Pharmaceutical
  • Quarterly report
  • Company
View report >

Quantum Genomics Corp. Analyst report

  • January 2022
  • 7 pages
  • World
  • East Asia
  • Heart Failure
  • Cardiovascular Disease
  • Broker research
  • Company
  • Number Of Enterprises
  • Dates Price
View report >

MiMedx Analyst report

  • January 2022
  • 35 pages
  • United States
  • World
  • Therapy
  • Cell Therapy
  • Broker research
  • Company
  • Drug Approval
  • Mortality Rate
View report >

CGuard Investor presentation

  • January 2022
  • 24 pages
  • World
  • United States
  • Stroke
  • Real Estate
  • Investor presentation
  • Company
View report >

DaVita Analyst report

  • January 2022
  • 12 pages
  • United States
  • North America
  • Chronic Disease
  • Healthcare
  • Broker research
  • Company
View report >

DarioHealth Analyst report

  • January 2022
  • 8 pages
  • United States
  • North America
  • Healthcare
  • Chronic Disease
  • Broker research
  • Company
  • Number Of Enterprises
  • Dates Price
View report >

Antibe Therapeutics Analyst report

  • January 2022
  • 6 pages
  • Canada
  • North America
  • Chronic Pain
  • Pharmaceutical
  • Broker research
  • Company
  • Drug Approval
  • Number Of Enterprises
View report >

Sequana Medical Investor presentation

  • January 2022
  • 50 pages
  • United States
  • North America
  • Heart Failure
  • Investor presentation
  • Company
  • Cancer Incidence
  • Hospital Discharge
View report >

ABIOMED Analyst report

  • January 2022
  • 9 pages
  • United States
  • World
  • Heart Failure
  • Specialty Hospital
  • Broker research
  • Company
  • Drug Approval
View report >

AstraZeneca Analyst report

  • January 2022
  • 15 pages
  • China
  • European Union
  • Infectious Disease
  • Vaccine
  • Broker research
  • Company
  • Drug Approval
View report >

Oramed Investor presentation

  • January 2022
  • 39 pages
  • China
  • Insulin
  • Type 2 Diabetes
  • Investor presentation
  • Company
  • Drug Approval
  • Diabetes Prevalence
View report >

Therapeutics Inc Analyst report

  • January 2022
  • 6 pages
  • Canada
  • North America
  • Banking
  • Hospital
  • Broker research
  • Company
  • Number Of Enterprises
  • Dates Price
View report >

MiMedx Analyst report

  • January 2022
  • 7 pages
  • Japan
  • East Asia
  • Arthritis
  • Broker research
  • Company
  • Number Of Enterprises
  • Dates Price
28 reports

Purchase Reports From Reputable Market Research Publishers

Company Analysis: Sanofi

  • $ 3000
  • January 2021
  • 69 pages

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Sanofi will see strong pharmaceutical revenue growth over the forecast period, ...

  • United States
  • Pharmaceutical
  • Respiratory Disease
  • Company research
  • Company
  • Pharmaceutical Revenue

Company Analysis: Novo Nordisk $ 3000 January 2021

Company Analysis: AstraZeneca $ 3000 January 2021

Asthma - Pipeline Review, H2 2020 $ 2000 October 2020

Stroke - Pipeline Review, H2 2020 $ 2000 October 2020


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on